190 related articles for article (PubMed ID: 37916324)
21. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
[TBL] [Abstract][Full Text] [Related]
22. Multiomics Analysis of Disulfidptosis Patterns and Integrated Machine Learning to Predict Immunotherapy Response in Lung Adenocarcinoma.
Liu J; Li H; Zhang N; Dong Q; Liang Z
Curr Med Chem; 2024 Apr; ():. PubMed ID: 38685772
[TBL] [Abstract][Full Text] [Related]
23. Typing and modeling of hepatocellular carcinoma based on disulfidptosis-related amino acid metabolism genes for predicting prognosis and guiding individualized treatment.
Chen X; Wang Z; Wu Y; Lan Y; Li Y
Front Oncol; 2023; 13():1204335. PubMed ID: 37637055
[TBL] [Abstract][Full Text] [Related]
24. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
25. Identification a unique disulfidptosis classification regarding prognosis and immune landscapes in thyroid carcinoma and providing therapeutic strategies.
Feng Z; Zhao Q; Ding Y; Xu Y; Sun X; Chen Q; Zhang Y; Miao J; Zhu J
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11157-11170. PubMed ID: 37347261
[TBL] [Abstract][Full Text] [Related]
26. Novel immune subtypes of lung adenocarcinoma identified through bioinformatic analysis.
Qin FL; Xu ZY; Yuan LQ; Chen WJ; Wei JB; Sun Y; Li SK
FEBS Open Bio; 2020 Sep; 10(9):1921-1933. PubMed ID: 32686362
[TBL] [Abstract][Full Text] [Related]
27. Identification of disulfidptosis related subtypes, characterization of tumor microenvironment infiltration, and development of DRG prognostic prediction model in RCC, in which
Xu K; Zhang Y; Yan Z; Wang Y; Li Y; Qiu Q; Du Y; Chen Z; Liu X
Front Immunol; 2023; 14():1205250. PubMed ID: 37426643
[TBL] [Abstract][Full Text] [Related]
28. Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer.
Dong X; Liao P; Liu X; Yang Z; Wang Y; Zhong W; Wang B
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629096
[TBL] [Abstract][Full Text] [Related]
29. Integrative analysis of single-cell and bulk RNA-sequencing data revealed disulfidptosis genes-based molecular subtypes and a prognostic signature in lung adenocarcinoma.
Wang H; Zhu X; Zhao F; Guo P; Li J; Du J; Shan G; Li Y; Li J
Aging (Albany NY); 2024 Feb; 16(3):2753-2773. PubMed ID: 38319721
[TBL] [Abstract][Full Text] [Related]
30. Molecular Characterization and Prognosis of Lactate-Related Genes in Lung Adenocarcinoma.
Guo Z; Hu L; Wang Q; Wang Y; Liu XP; Chen C; Li S; Hu W
Curr Oncol; 2023 Feb; 30(3):2845-2861. PubMed ID: 36975430
[TBL] [Abstract][Full Text] [Related]
31. Crosstalk among disulfidptosis-related lncRNAs in lung adenocarcinoma reveals a correlation with immune profile and clinical prognosis.
Liu S; Wang S; Guo J; Wang C; Zhang H; Lin D; Wang Y; Hu X
Noncoding RNA Res; 2024 Sep; 9(3):772-781. PubMed ID: 38590434
[TBL] [Abstract][Full Text] [Related]
32. Construction of a novel disulfidptosis-related signature for improving outcomes in hepatocellular carcinoma: Observational study.
Chen X; Liang Q; Zhou Y
Medicine (Baltimore); 2023 Oct; 102(40):e35423. PubMed ID: 37800779
[TBL] [Abstract][Full Text] [Related]
33. Genomic and immunogenomic analysis of three prognostic signature genes in LUAD.
Feng HM; Zhao Y; Yan WJ; Li B
BMC Bioinformatics; 2023 Jan; 24(1):19. PubMed ID: 36650426
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Prediction Value and Biological Functions of Non-Apoptotic Regulated Cell Death Genes in Lung Adenocarcinoma.
Li HL; Wang JX; Dai HW; Liu JJ; Liu ZY; Zou MY; Zhang L; Wang WR
Chin Med Sci J; 2023 Sep; 38(3):178-190. PubMed ID: 37622313
[TBL] [Abstract][Full Text] [Related]
35. Novel immunogenic cell death-related risk signature to predict prognosis and immune microenvironment in lung adenocarcinoma.
Li Q; Tang Y; Wang T; Zhu J; Zhou Y; Shi J
J Cancer Res Clin Oncol; 2023 Jan; 149(1):307-323. PubMed ID: 36575346
[TBL] [Abstract][Full Text] [Related]
36. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
37. A Comprehensive Prognostic and Immune Analysis of Ferroptosis-Related Genes Identifies SLC7A11 as a Novel Prognostic Biomarker in Lung Adenocarcinoma.
Qian L; Wang F; Lu SM; Miao HJ; He X; Feng J; Huang H; Shi RF; Zhang JG
J Immunol Res; 2022; 2022():1951620. PubMed ID: 35509981
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of immune-related genes in the tumor microenvironment of lung adenocarcinoma and lung squamous cell carcinoma.
Qu Y; Cheng B; Shao N; Jia Y; Song Q; Tan B; Wang J
Aging (Albany NY); 2020 Mar; 12(6):4757-4777. PubMed ID: 32209727
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment.
Yu L; Cao S; Li J; Han B; Zhong H; Zhong R
Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738
[TBL] [Abstract][Full Text] [Related]
40. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]